Zhongshan Laibo Ruichen Biomedicine Co., Ltd., founded in 2021, is a biopharmaceutical company dedicated to the independent R&D and commercialization of innovative therapeutics for bone and joint diseases.

Our R&D team is led by Prof. Wei Yao, a renowned expert in bone and joint regenerative medicine from UC Davis. Our core members are  researchers and scientists with backgrounds from globally recognized institutions and extensive professional experience at leading pharmaceutical companies such as Merck, Bayer, and WuXi AppTec.

Rabpharma specializes in developing first-in-class therapeutics for skeletal disorders. Our innovative drug, RAB001, targeting to the treatment of osteonecrosis, has completed Phase I trials both in the U.S. and China. Since December 2024, a Phase II clinical trial has been initiated in 25 hospitals all around China. At the same time, we are advancing many  preclinical-stage innovative drugs targeting a broader range of bone and joint diseases.

Since our establishment four years ago, Rabpharma has completed 3 successful funding rounds, which accelerates the development of our clinical programs and expands the R&D pipeline, reinforcing our goal to become a globally competitive company in the field of bone and joint therapeutics.

Ultimately, we remain committed to our mission: to provide patients with more and better treatment options for bone and joint disorders.